STOCKHOLM, Sweden, Feb. 11, 2004 (PRIMEZONE) -- Investor's share of the voting rights and share capital in AstraZeneca has changed through the divestment of 21,200,000 shares.
After the sale, Investor's holding in AstraZeneca now amounts to 63,465,810 shares corresponding to 3.75 percent of the voting rights and share capital. On December 31, 2003, Investor's holding in AstraZeneca amounted to 5.0 percent of the votes and capital.
In a statement, Investor President and CEO Marcus Wallenberg said: "We have decided to reduce our leverage and strengthen our financial flexibility. We continue to believe strongly in AstraZeneca and the company is still our largest holding."
INVESTOR AB
For further information:
Fredrik Lindgren, Vice President, Corporate Communications: +46 8 614 20 31, +46 735 24 20 31
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/02/11/20040211BIT00350/wkr0001.doc
http://www.waymaker.net/bitonline/2004/02/11/20040211BIT00350/wkr0002.pdf